Roche obtains FDA 510(k) Approval for Cobas
Roche’s cobas MRSA/SA Test has received 510(k) approval from the US Food and Drug Administration (FDA) for the early and […]
Say something
Tags: Antibiotic-resistant bacteria, Bacteria, Bacterial diseases, chlamydia/gonorrhea, Cobas, Head, Health/Medical/Pharmaceuticals, healthcare-associated infections, HPV, Infections, Methicillin-resistant Staphylococcus aureus, Microbiology, molecular solution, MRSA/SA infections, overall management, Paul Brown, Roche, Roche Molecular Diagnostics, Staphylococcaceae, Staphylococcus aureus, United States, US Food and Drug Administration
Wockhardt hiving off R&D business
Drug maker Wockhardt has announced it will spin off its R&D business and list the new company on stock exchange on January 1, 2009. The company thus has followed similar moves by other pharma companies, who have hived off their research and development units.
-
-
Flipkart Health+ App Launched
06-04-2022
